Ascertainment of Side Effects in Psychopharmacologic Clinical Trials
Since the era of modern pharmacologic treatment of psychiatric disorders began in the mid-1950s, much progress has been made in techniques to assess the efficacy of proposed therapeutic agents. This has come about for a variety of reasons including the amendment to the U.S. Food, Drug, and Cosmetics Law in 1962 that requires proof of efficacy before marketing of prescription medications is permitted. Assessment or proof of safety prior to marketing had been a requirement for many years.
KeywordsPlacebo Marketing Assure
Unable to display preview. Download preview PDF.
- Fisher S, Bryant SG, Kluge RM (1987) Detecting adverse drug reactions in post marketing surveillance: interview-validity. Drug Inform J 21: 173–183Google Scholar
- Fletcher RH, Fletcher SW, Wagner EH (1982) Clinical epidemiology — the essentials. Williams and Wilkins, BaltimoreGoogle Scholar
- Jones JK, Herman RL (1986) The future of adverse drug reaction diagnosis: computers, clinical judgement and the logic of uncertainty. Drug Inform J 20 /4: 445–535Google Scholar
- O’Neill RT (1988) Assessment of Safety. In: Peace KE (ed) Biopharmaceutical statistics for drug development. Dekker, New YorkGoogle Scholar
- Peace KE (1987) Design, monitoring and analysis issues relative to adverse events. Drug Inform J 21: 21–28Google Scholar
- Speiss-Kiefer C, Grohmann R, Schmidt LG, Ruther E (1988) Six years of drug surveillance in psychiatric inpatients. Pharm Med 3: 341–348Google Scholar
- Stephens MDP (1985) The detection of new adverse drug reactions. Macmillan, LondonGoogle Scholar